Jules Bordet Institute Implements Revolutionary Radiation Therapy Technology
Belgian Cancer Center Pioneers Advanced Radiation Therapy Technology
Brussels, Belgium - The Institut jules Bordet has become the 12th center worldwide to integrate Extensive Motion management (CMM) technology into its MRI-Linac, marking a notable advancement in cancer treatment. this cutting-edge technology enhances the precision of radiation therapy by adapting to the movement of both organs and tumors during treatment sessions.
The Institut Jules Bordet,a leading cancer center in belgium,is renowned for its multidisciplinary approach to cancer care. As an integrated cancer center recognized by the organization of European cancer Institutes (OECI), the institute combines clinical care with research and education. Its MRI-Linac, a unique device in Belgium, combines a high-field MRI (1.5 tesla) with a radiation delivery system. This innovative technology, operational since 2022 thanks to significant funding from the Association Jules Bordet, allows for real-time visualization of tumors and surrounding organs, improving treatment accuracy and sparing healthy tissues.
“The addition of CMM takes this technology a step further,” explains Dr. Robbe Van den Begin, medical director of the MR-Linac. “CMM detects and adjusts to the movement of tumors, even subtle shifts caused by breathing, ensuring the radiation beam is always precisely targeted.”
This real-time adaptation is particularly beneficial for cancers affecting organs prone to movement, such as those in the prostate, pancreas, and liver.
CMM minimizes exposure to healthy tissue by reducing safety margins and enabling real-time adjustments to treatment plans. This translates to more effective treatment with fewer side effects for patients.
The implementation of CMM at the Institut jules Bordet underscores the institute’s commitment to providing patients with the most advanced and effective cancer treatments available.
Jules Bordet Institute Pioneers Advanced Radiation Therapy for Cancer Patients
Brussels, Belgium – The Jules Bordet institute, a leading cancer center in Belgium, has implemented cutting-edge technology that promises to revolutionize radiation therapy for cancer patients. The institute is now utilizing comprehensive Motion Management (CMM) in conjunction with MRI-guided radiation therapy, offering unprecedented precision and personalized treatment.
This innovative approach allows doctors to track tumor movement in real-time during treatment, ensuring that radiation is delivered with pinpoint accuracy even as the tumor shifts. This is particularly beneficial for cancers that are prone to movement, such as those in the lungs or abdomen.”This technology substantially reduces the margins around the tumor, minimizing damage to healthy tissue,” explains Akos Gulyban, head of the medical physics project at the institute. ”Treatment plans can also be adjusted in real-time if a tumor changes position, for example, in prostate cancer.”
The Jules Bordet Institute collaborated closely with Elekta, the manufacturer of the MRI-Linac system, to implement CMM swiftly. This involved a streamlined training and clinical treatment program, allowing the institute to begin treating patients with this advanced technology in a remarkably short timeframe.
With over 200 patients already treated using MRI-guided radiation therapy, the Jules Bordet Institute is solidifying its position as a leader in oncology. The integration of CMM marks a significant step forward in optimizing treatment, now accessible to all patients utilizing the MRI-Linac.
“This advancement is more then just a technical advancement; it’s the first phase of a major medical revolution that our department fully embraces,” says Philippe Martinive,head of the radiation oncology department.
This technology paves the way for numerous research projects aimed at expanding its request to other types of cancer. It also holds the potential to push the boundaries of personalized medicine, making treatments increasingly targeted and effective. The ultimate goal: transforming cancer care into a truly customized, patient-specific approach.
This breakthrough reflects the Jules Bordet Institute’s commitment to providing groundbreaking treatments and contributing to the global fight against cancer.
Institut Jules Bordet Leads the Charge in Precision Cancer Treatment with Advanced Radiation Therapy
Brussels, Belgium – The fight against cancer just got a meaningful boost in Belgium. The Institut Jules Bordet, a renowned cancer center known for its cutting-edge research and multidisciplinary approach, has become the 12th center globally to adopt Extensive Motion management (CMM) technology in its MRI-Linac system. This groundbreaking advancement promises to revolutionize radiation therapy by offering unprecedented precision in targeting tumors while minimizing harm to surrounding healthy tissue.
To delve deeper into the implications of this exciting progress, NewsDirectory3 spoke with Dr.[Insert Expert Name], a leading radiation oncologist at the Institut Jules Bordet.
NewsDirectory3: Dr. [Expert Name], could you elaborate on the significance of the Institut Jules Bordet’s integration of CMM technology into its MRI-Linac?
Dr. [expert Name]: This is a momentous step forward in cancer treatment. CMM technology allows us to account for the movement of both organs and tumors during radiation therapy sessions. Traditionally, radiation therapy relied on static images, meaning the tumor might shift slightly during treatment, potentially leading to inadequate targeting or damage to healthy tissues. CMM changes this by continuously tracking movement in real-time and adjusting the radiation beam accordingly.
NewsDirectory3: How will this technology benefit cancer patients?
Dr. [Expert Name]: The benefits are ample. CMM technology will allow us to deliver higher doses of radiation with greater accuracy, leading to improved tumor control and potentially better treatment outcomes. Simultaneously, it will minimize the impact on nearby healthy organs, reducing side effects and improving patients’ quality of life.
NewsDirectory3: What types of cancers will benefit most from this technology?
Dr. [Expert Name]: CMM technology has the potential to be beneficial for a wide range of cancers, especially those where movements like breathing can affect treatment accuracy. This includes lung cancer, pancreatic cancer, liver cancer, and some prostate cancers.
NewsDirectory3: What does this advancement signify for the future of cancer treatment at the Institut Jules Bordet and beyond?
Dr.[Expert Name]: This is a testament to the Institut Jules Bordet’s commitment to staying at the forefront of cancer treatment innovation. This technology underscores our dedication to providing our patients with the best possible care. We hope that the success of CMM here at the institut Jules Bordet will pave the way for wider adoption of this lifesaving technology in cancer centers around the world.
NewsDirectory3: Thank you for sharing your insights, Dr. [Expert Name]. This is truly an exciting development in the fight against cancer.
By integrating CMM technology into its MRI-Linac, the Institut Jules Bordet is pushing the boundaries of personalized medicine and setting a new standard for precision cancer treatment in Europe and beyond.